Selected article for: "dexamethasone treatment and group difference"
Author: Ranjbar, Keivan; Moghadami, Mohsen; Mirahmadizadeh, Alireza; Fallahi, Mohammad Javad; Khaloo, Vahid; Shahriarirad, Reza; Erfani, Amirhossein; Khodamoradi, Zohre; Gholampoor Saadi, Mohammad Hasan
Title: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial
  • Cord-id: yh98uxdb
  • Document date: 2021_4_10
    • ID: yh98uxdb
    Snippet: BACKGROUND: Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. METHODS: In this prospect
    Document: BACKGROUND: Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. METHODS: In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8). RESULTS: There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040). CONCLUSION: In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. TRIAL REGISTRATION: The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1).

    Search related documents:
    Co phrase search for related documents
    • accurate estimate and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • acute respiratory and add treatment: 1, 2, 3, 4, 5, 6
    • acute respiratory and administration dosage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low dose dexamethasone: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and low dose methylprednisolone: 1, 2, 3, 4, 5
    • acute respiratory and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung injury effective: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung involvement rapid progression: 1, 2
    • acute respiratory illness and admission day: 1, 2, 3, 4, 5
    • acute respiratory illness and low mortality: 1, 2, 3, 4, 5, 6
    • acute respiratory illness and low mortality rate: 1, 2
    • acute respiratory illness and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute respiratory illness and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome coronavirus and add treatment: 1, 2, 3, 4
    • acute respiratory syndrome coronavirus and administration dosage: 1, 2, 3, 4, 5, 6